The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B

Liver stiffness (LS) as assessed by transient elastography (TE) can change longitudinally in patients with chronic hepatitis B (CHB). The aim of this study was to identify the factors that improve LS. Between April 2007 and December 2012, 151 patients with CHB who underwent two TE procedures with an...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and molecular hepatology 2015-03, Vol.21 (1), p.32-40
Main Authors: Yo, In Ku, Kwon, Oh Sang, Park, Jin Woong, Lee, Jong Joon, Lee, Jung Hyun, Won, In Sik, Na, Sun Young, Jang, Pil Kyu, Park, Pyung Hwa, Choi, Duck Joo, Kim, Yun Soo, Kim, Ju Hyun
Format: Article
Language:English
Subjects:
Adult
Aged
Alanine Transaminase - blood
Antigens
Antiviral Agents - therapeutic use
Chronic hepatitis B
DNA, Viral - blood
Elasticity Imaging Techniques
Female
Hepatic fibrosis
Hepatitis B
Hepatitis B e Antigens - blood
Hepatitis B virus - genetics
Hepatitis B, Chronic - diagnostic imaging
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - pathology
Humans
Laboratories
Liver cirrhosis
Liver stiffness
Logistic Models
Longitudinal Studies
Male
Middle Aged
Original
Patients
Statistical analysis
Transient elastography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liver stiffness (LS) as assessed by transient elastography (TE) can change longitudinally in patients with chronic hepatitis B (CHB). The aim of this study was to identify the factors that improve LS. Between April 2007 and December 2012, 151 patients with CHB who underwent two TE procedures with an interval of about 2 years were enrolled. Ninety-six of the 151 patients were treated with nucleos(t)ide analogues [the antiviral therapy (+) group], while the remaining 55 patients were not [the antiviral therapy (-) group]. The two groups of patients were stratified according to whether they exhibited an improvement or a deterioration in LS during the study period (defined as an LS change of ≤0 or >0 kPa, respectively, over a 1-year period), and their data were compared. No differences were observed between the antiviral therapy (+) and (-) groups with respect to either their clinical characteristics or their initial LS. The observed LS improvement was significantly greater in the antiviral therapy (+) group than in the antiviral therapy (-) group (-3.0 vs. 0.98 kPa, P=0.011). In the antiviral therapy (+) group, the initial LS was higher in the LS improvement group (n=63) than in the LS deterioration group (n=33; 7.9 vs. 4.8 kPa, P
ISSN:2287-2728
2287-285X
DOI:10.3350/cmh.2015.21.1.32